Project Grant 2037190

The National Science Foundation awarded $256,000 to Optave Diagnostics LLC through the Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a prototype endoscopic probe for molecular imaging and diagnosis of cancerous prostate pathologies. The 12-month project grant will support the creation of a medical device using photoacoustic imaging and acoustic lens technology to aid in the detection and diagnosis of prostate cancer. The proposed endoscopic probe offers an alternative...

This $256,000 National Science Foundation Project Grant under the Engineering (47.041) program will support the development of an artificial intelligence-based system for analyzing multiparametric magnetic resonance imaging (MRI) scans to detect prostate lesions. The awardee, Taurus Diagnostics, Inc., will create a novel prostate cancer diagnostic platform leveraging artificial intelligence image analysis for high sensitivity and specificity. Key objectives include developing methods to...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $245,087 to the University of Delaware from June 1, 2025 to May 31, 2027. The primary objectives are to: Curate a comprehensive dataset of 300 public and 50 Memorial Sloan Kettering MRI scans, annotated with corresponding PIRADS radiology reports, to enable machine-readable extraction of radiologist reasoning processes. Develop a Prostate Vision Language Model...

This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to create a new surgical probe prototype for laparoscopic prostate cancer resection procedures. The $161,000 award will fund the development and testing of a probe specifically designed for use with Positron Emission Tomography (PET) radiotracers, which can better...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Regents of the University of Michigan aims to develop a real-time functional photoacoustic imaging platform to accurately detect and characterize the aggressiveness of prostate cancer. The $568,151 award, effective February 3, 2025 through January 31, 2030, will support the optimization of photoacoustic contrast agents, evaluation of the imaging platform in mouse models, and...

This $300,000 Project Grant awarded by the National Science Foundation (NSF) under the Integrative Activities (CFDA 47.083) program supports the development of an innovative, intelligent surgical probe for prostate cancer treatment. The project aims to create an edge artificial intelligence (AI) system-on-chip for bioimpedance analysis that can accurately distinguish cancerous from healthy tissue during prostate removal surgery. The novel technology being developed includes an adaptive filter to...

This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $538,553.00 to the University of Miami to conduct longitudinal imaging and liquid biopsy studies to identify markers for prostate cancer radiotherapy outcomes. The goal is to develop a multivariable model that incorporates pre-treatment and longitudinal multiparametric MRI features and circulating tumor cells to guide physicians' decisions on radiation therapy...

This Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Metastx LLC, a small business located in Pittsburgh, PA, provides $399,954 in funding from Jul 1, 2025 to Jun 30, 2026. The project aims to develop a novel predictive model for metastatic potential in early-stage prostate cancer patients by integrating epithelial-mesenchymal transition signature markers with advanced imaging and machine learning techniques. The goal is to...

This STTR Phase I project, funded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to advance the development and evaluation of a hand-held induction heater device for treating pancreatic and prostate cancer using magnetic fluid hyperthermia (MFH) technology. The project, awarded to Ihnnova LLC, a small business located in Guánica, Puerto Rico, will receive $275,000 in funding over the period of October 1, 2024 to...

This federal Project Grant award of $185,171 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) will support research to optimize polymeric chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI) agents for prostate cancer detection. The research aims to synthesize and characterize CEST MRI agents with varying charge and...